References
Kelmenson V.A. Treatment of pulmonary aspergillosis. Dis. Chest 1959;36 Article
Young RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT. Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore). 1970 Mar;49(2):147-73 Article
Carrizosa J, Kohn C, Levison ME. Experimental aspergillus endocarditis in rabbits. J Lab Clin Med. 1975 Nov;86(5):746-53 Article
Arroyo J, Medoff G, Kobayashi GS. Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine. Antimicrob Agents Chemother. 1977 Jan;11(1):21-5 Article
DeGregorio MW, Lee WM, Linker CA, Jacobs RA, Ries CA. Fungal infections in patients with acute leukemia. Am J Med. 1982 Oct;73(4):543-8 Article
Polak A, Scholer HJ, Wall M. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Chemotherapy. 1982;28(6):461-79 Article
Weiland D, Ferguson RM, Peterson PK, Snover DC, Simmons RL, Najarian JS. Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis, and management. Ann Surg. 1983 Nov;198(5):622-9 Article
Albelda SM, Talbot GH, Gerson SL, Miller WT, Cassileth PA. Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia. Am Rev Respir Dis. 1985 Jan;131(1):115-20 Article
Gerson SL, Talbot GH, Lusk E, Hurwitz S, Strom BL, Cassileth PA. Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to its diagnosis. J Clin Oncol. 1985 Aug;3(8):1109-16 Article
Spearing RL, Pamphilon DH, Prentice AG. Pulmonary aspergillosis in immunosuppressed patients with haematological malignancies. Q J Med. 1986 Jun;59(230):611-25 Article
Longman LP, Martin MV. A comparison of the efficacy of itraconazole, amphotericin B and 5-fluorocytosine in the treatment of Aspergillus fumigatus endocarditis in the rabbit. J Antimicrob Chemother. 1987 Nov;20(5):719-24 Article
De Beule K, De Doncker P, Cauwenbergh G, Koster M, Legendre R, Blatchford N, Daunas J, Chwetzoff E. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses. 1988 Sep;31(9):476-85 Article
Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989 Jun;86(6 Pt 2):791-800 Article
Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989 Mar;37(3):310-44 Article
. .
Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol. 1990 Sep;23(3 Pt 2):607-14 Article
Martino P, Girmenia C, Venditti M, Micozzi A, Gentile G, Raccah R, Martinelli E, Rendina E, Mandelli F. Spontaneous pneumothorax complicating pulmonary mycetoma in patients with acute leukemia. Rev Infect Dis. 1990 Jul-Aug;12(4):611-7 Article
Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med. 1991 Mar 7;324(10):654-62 Article
Kreisel W, Köchling G, von Schilling C, Azemar M, Kurzweil B, Dölken G, Lindemann A, Blum U, Windfuhr M, Müller J. Therapy of invasive aspergillosis with itraconazole: improvement of therapeutic efficacy by early diagnosis. Mycoses. 1991 Sep-Oct;34(9-10):385-94 Article
Palmer LB, Greenberg HE, Schiff MJ. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax. 1991 Jan;46(1):15-20 Article
Ringdén O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, Viviani MA, Gorin NC, Klastersky J, Fenaux P, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother. 1991 Oct;28 Suppl B:73-82 Article
van’t Wout JW, Novakova I, Verhagen CA, Fibbe WE, de Pauw BE, van der Meer JW. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect. 1991 Jan;22(1):45-52 Article
Denning DW, Hanson LH, Perlman AM, Stevens DA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis. 1992 Jan;15(1):21-34 Article
Lupinetti FM, Behrendt DM, Giller RH, Trigg ME, de Alarcon P. Pulmonary resection for fungal infection in children undergoing bone marrow transplantation. J Thorac Cardiovasc Surg. 1992 Sep;104(3):684-7 PubMed
. .
Weinberger M, Elattar I, Marshall D, Steinberg SM, Redner RL, Young NS, Pizzo PA. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore). 1992 Jan;71(1):24-43 Article
Wong K, Waters CM, Walesby RK. Surgical management of invasive pulmonary aspergillosis in immunocompromised patients. Eur J Cardiothorac Surg. 1992;6(3):138-42; discussion 143Article
Young VK, Maghur HA, Luke DA, McGovern EM. Operation for cavitating invasive pulmonary aspergillosis in immunocompromised patients. Ann Thorac Surg. 1992 Apr;53(4):621-4 Article
George D, Kordick D, Miniter P, Patterson TF, Andriole VT. Combination therapy in experimental invasive aspergillosis. J Infect Dis. 1993 Sep;168(3):692-8 Article
McWhinney PH, Kibbler CC, Hamon MD, Smith OP, Gandhi L, Berger LA, Walesby RK, Hoffbrand AV, Prentice HG. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years’ experience. Clin Infect Dis. 1993 Sep;17(3):397-404 Article
Massard G, Lioure B, Wihlm JM, Morand G. Resection of mycotic lung sequestra after invasive aspergillosis. Ann Thorac Surg. 1993 Feb;55(2):563-4 Article
Moreau P, Zahar JR, Milpied N, Baron O, Mahé B, Wu D, Germaud P, Despins P, Delajartre AY, Harousseau JL. Localized invasive pulmonary aspergillosis in patients with neutropenia. Effectiveness of surgical resection. Cancer. 1993 Dec 1;72(11):3223-6 Article
Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine (Baltimore). 1993 Mar;72(2):78-89 Article
Singh N, Mieles L, Yu VL, Gayowski T. Invasive aspergillosis in liver transplant recipients: association with candidemia and consumption coagulopathy and failure of prophylaxis with low-dose amphotericin B. Clin Infect Dis. 1993 Nov;17(5):906-8 Article
Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med. 1994 Aug;97(2):135-44 Article
Khoo SH, Denning DW. Invasive aspergillosis in patients with AIDS. Clin Infect Dis. 1994 Aug;19 Suppl 1:S41-8 Article
Martino R, Nomdedéu J, Altés A, Sureda A, Brunet S, Martínez C, Domingo-Albós A. Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases. Bone Marrow Transplant. 1994 Mar;13(3):265-9 Article
Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol. 1994 Apr;86(4):754-60 Article
Temeck BK, Venzon DJ, Moskaluk CA, Pass HI. Thoracotomy for pulmonary mycoses in non-HIV-immunosuppressed patients. Ann Thorac Surg. 1994 Aug;58(2):333-8 Article
Verweij PE, Donnelly JP, Kullberg BJ, Meis JF, De Pauw BE. Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection. 1994 Mar-Apr;22(2):81-5 Article
Walsh JJ, Hiemenz JW, Seibel N, Anassie EJ. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis (abstract no M69). Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando) Washington, D C American Society for Microbiology, 247 (abstract) 1994
Denning DW, Hall L, Jackson M, Hollis S. Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. Antimicrob Agents Chemother. 1995 Aug;39(8):1809-14 Article
End A, Helbich T, Wisser W, Dekan G, Klepetko W. The pulmonary nodule after lung transplantation. Cause and outcome. Chest. 1995 May;107(5):1317-22 Article
Guillemain R, Lavarde V, Amrein C, Chevalier P, Guinvarc’h A, Glotz D. Invasive aspergillosis after transplantation. Transplant Proc. 1995 Feb;27(1):1307-9 Article
Hiemenz JW, Lister J, Anassie EJ et al. Emergency use amphoterecin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical control comparison with amphotericin B (abstract no 3383). Blood, 86, 849a (abstract)1995
Kac G, Roux P, Poirot JL, Meyohas MC, Cadranel J, Chouaid C et al. Aspergillus et aspergilloses: etude retrospective dans deux hopitaux parisiens. Mycologie Medicale 1995; 5: 75-85.
Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med. 1995 May 22;155(10):1093-8 Article
Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis. 1995 Nov;21(5):1145-53Article
Pagano L, Ricci P, Nosari A, Tonso A, Buelli M, Montillo M, Cudillo L, Cenacchi A, Savignana C, Melillo L. Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano Malat. Br J Haematol. 1995 Mar;89(3):500-5 Article
Robinson LA, Reed EC, Galbraith TA, Alonso A, Moulton AL, Fleming WH. Pulmonary resection for invasive Aspergillus infections in immunocompromised patients. J Thorac Cardiovasc Surg. 1995 Jun;109(6):1182-96; discussion 1196-7 Article
von Eiff M, Roos N, Schulten R, Hesse M, Zühlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration. 1995;62(6):341-7 Article
von Eiff M, Zühlsdorf M, Roos N, Hesse M, Schulten R, van de Loo J. Pulmonary fungal infections in patients with hematological malignancies – diagnostic approaches. Ann Hematol. 1995 Mar;70(3):135-41 Article
Yeldandi V, Laghi F, McCabe MA, Larson R, O’Keefe P, Husain A, Montoya A, Garrity ER Jr. Aspergillus and lung transplantation. J Heart Lung Transplant. 1995 Sep-Oct;14(5):883-90PubMed
Böhme A, Hoelzer D. Liposomal amphotericin B as early empiric antimycotic therapy of pneumonia in granulocytopenic patients. Mycoses. 1996 Nov-Dec;39(11-12):419-26 Article
Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis. 1996 May;173(5):1208-15 Article
. .
Caras WE, Pluss JL. Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Mayo Clin Proc. 1996 Jan;71(1):25-30 Article
Ellis M, Meunier SF, Bogaerts M, Van Der Cam B, Doyen C, Marinus A, Collette L, Sylvester R, EORTC IFICG. Randomised multicentre trial of 1mg/kg versus 4mg/kg liposomal amphotericin B (AmBisome) in the treatment of invasive aspergillosis. Abstracts of the 36th ICAAC, #LM39, 287(abstract) 1996.
Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis. 1996 May;22 Suppl 2:S133-44 Article
Patterson TF, Peters J, Levine SM, Anzueto A, Bryan CL, Sako EY, Miller OL, Calhoon JH, Rinaldi MG. Systemic availability of itraconazole in lung transplantation. Antimicrob Agents Chemother. 1996 Sep;40(9):2217-20 Article
Wallace TF, Paetznick V, Cossum PA, Anaissie EJ. Nyotran (Liposomal nystatin) activity against disseminated Aspergillus fumigatus in neutropenic mice. Abstract #B53 of the 36th ICAAC, (abstract) 1996.
Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation. 1996 Mar 27;61(6):915-9Article
Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, Solary E, Piard F, Petrella T, Bonnin A, Couillault G, Dumas M, Guy H. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997 Jan;15(1):139-47 Article
Habicht JM, Gratwohl A, Tamm M, Drewe J, Proske M, Stulz P. Diagnostic and therapeutic thoracic surgery in leukemia and severe aplastic anemia. J Thorac Cardiovasc Surg. 1997 Jun;113(6):982-8 Article
Hoover M, Morgan ER, Kletzel M. Prior fungal infection is not a contraindication to bone marrow transplant in patients with acute leukemia. Med Pediatr Oncol. 1997 Apr;28(4):268-73 Article
Mehta J, Kelsey S, Chu P, Powles R, Hazel D, Riley U, Evans C, Newland A, Treleaven J, Singhal S. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant. 1997 Jul;20(1):39-43 Article
Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest. 1997 Aug;112(2):541-8 Article
Karim M, Alam M, Shah AA, Ahmed R, Sheikh H. Chronic invasive aspergillosis in apparently immunocompetent hosts. Clin Infect Dis. 1997 Apr;24(4):723-33 Article
Verweij PE, Denning DW. Diagnostic and therapeutic strategies in invasive aspergillosis. Semin Respir Crit Care Med. 1997;18(3):205-15 Article
Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997 Jun;175(6):1459-66 Article
White MH, Anaissie EJ, Kusne S, Wingard JR, Hiemenz JW, Cantor A, Gurwith M, Du Mond C, Mamelok RD, Bowden RA. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis. 1997 Apr;24(4):635-42 Article
Oakley KL, Moore CB, Denning DW. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.Antimicrob Agents Chemother. 1997 May;41(5):1124-6 Article
Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother. 1997 Jul;41(7):1504-7 Article
Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, Cornelissen J, Herbrecht R, van der Lelie H, Hoogsteden HC, Verbrugh HA, de Marie S. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998 Oct;103(1):205-12 Article
Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey GA. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis. 2000 Apr;30(4):696-709 Article
Yeghen T, Kibbler CC, Prentice HG, Berger LA, Wallesby RK, McWhinney PH, Lampe FC, Gillespie S. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis. 2000 Oct;31(4):859-68 Article
Pidhorecky I, Urschel J, Anderson T. Resection of invasive pulmonary aspergillosis in immunocompromised patients. Ann Surg Oncol. 2000 May;7(4):312-7 Article
Petraitiene R, Petraitis V, Groll AH, Sein T, Piscitelli S, Candelario M, Field-Ridley A, Avila N, Bacher J, Walsh TJ. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother. 2001 Mar;45(3):857-69 Article
Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ. 2001 Mar 10;322(7286):579-82Article
Petraitiene R, Petraitis V, Groll AH, Sein T, Schaufele RL, Francesconi A, Bacher J, Avila NA, Walsh TJ. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother. 2002 Jan;46(1):12-23 Article
Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002 Mar;21(3):240-8 Article
Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, van Burik JA, Laverdiere M, Safrin S, Wingard JR. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002 Aug 15;35(4):359-66 Article
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis. N Engl J Med. 2002 Aug 8;347(6):408-15 Article
Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002 Mar 1;34(5):563-71 Article
Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002 Aug;46(8):2546-53 Article
Speich R, Dutly A, Naef R, Russi EW, Weder W, Boehler A. Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. Swiss Med Wkly. 2002 Aug 10;132(31-32):455-8 Article
Luque JC, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother. 2003 Apr;47(4):1452-5 Article
Gow KW, Hayes-Jordan AA, Billups CA, Shenep JL, Hoffer FA, Davidoff AM, Rao BN, Schropp KP, Shochat SJ. Benefit of surgical resection of invasive pulmonary aspergillosis in pediatric patients undergoing treatment for malignancies and immunodeficiency syndromes. J Pediatr Surg. 2003 Sep;38(9):1354-60 Article
Denning DW. Echinocandin antifungal drugs. Lancet. 2003 Oct 4;362(9390):1142-51 Article
Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003 Aug;41(8):3623-6 Article
Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S188-224 Article
Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004 Sep 15;39(6):797-802 Article
Kohno S, Masaoka T, Yamaguchi H, Mori T, Urabe A, Ito A, Niki Y, Ikemoto H. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis. 2004;36(5):372-9 Article
Matt P, Bernet F, Habicht J, Gambazzi F, Gratwohl A, Zerkowski HR, Tamm M. Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia.CHEST 126 6 DEC 2004 1783-1788 Article
Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin Infect Dis. 2004 Oct 15;39(8):1241-4 Article
Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004 Jun;48(6):2166-72 Article
Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother. 2004 Oct;54(4):803-8Article
Hall P, Kennedy G, Morton J, Hill GR, Durrant S. Twenty-four hour continuous infusion of amphotericin B for the treatment of suspected or proven fungal infection in haematology patients. Intern Med J. 2005 Jun;35(6):374 Article
Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother. 2005 Dec;49(12):4867-75 Article
Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, DePauw B, Schlamm HT, Troke P, Bennett JE; European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG); Pfizer Global Aspergillus Study Group. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis. 2005 Nov 15;41(10):1448-52 Article
Sionov E, Mendlovic S, Segal E. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect. 2006 Aug;53(2):131-9 Article
Maharom P, Thamlikitkul V. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate. J Med Assoc Thai. 2006 Nov;89 Suppl 5:S118-24 Article
Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.J Infect. 2006 May 5 Article
Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ, Lewis R, Wiederhold N, Holland SM, Petraitiene R, Walsh TJ, Segal BH. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother. 2006 Feb;50(2):422-7 Article
Singh N, Limaye AP, Forrest G, Safdar N, Munoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, Del Busto R, Aguado JM, Fisher RA, Klintmalm GB, Miller R, Wagener MM, Lewis RE, Kontoyiannis DP, Husain S. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.Transplantation. 2006 Feb 15;81(3):320-6. Article
Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH, Killar J, Taylor A, Kartsonis N, Patterson TF, Aoun M, Caillot D, Sable C; Caspofungin Combination Therapy Study Group. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2006 Dec 15;107(12):2888-97 Article
Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med. 2006 Jun;119(6):527.e17-24 Article
Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006 Nov 11;136(45-46):739-42Article
Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. Voriconazole therapeutic drug monitoring.Antimicrob Agents Chemother. 2006 Apr;50(4):1570-2. Article
Glasmacher A, Cornely OA, Orlopp K, Reuter S, Blaschke S, Eichel M, Silling G, Simons B, Egerer G, Siemann M, Florek M, Schnitzler R, Ebeling P, Ritter J, Reinel H, Schutt P, Fischer H, Hahn C, Just-Nuebling G. Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. J Antimicrob Chemother. 2005 Nov 24Article
Nosari A, Ravini M, Cairoli R, Cozzi P, Marbello L, Marenco P, Grillo G, Morra E. Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. Bone Marrow Transplant. 2007 May;39(10):631-5 Article
Cesaro S, Cecchetto G, Corti FD, Dodero P, Giacchino M, Caviglia I, Fagioli F, Livadiotti S, Salin F, Caselli D, Castagnola E. Results of a multicenter retrospective study of a combined medical and surgical approach to pulmonary aspergillosis in pediatric neutropenic patients. Pediatr Blood Cancer. 2007 Dec;49(7):909-13 Article
Anttila VJ, Salonen J, Ylipalosaari P, Koivula I, Riikonen P, Nikoskelainen J. A retrospective nationwide case study on the use of a new antifungal agent: patients treated with caspofungin during 2001-2004 in Finland. Clin Microbiol Infect. 2007 Jun;13(6):606-12 Article
Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R; AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007 May 15;44(10):1289-97 Article
Pascual A, Nieth V, Calandra T, Bille J, Bolay S, Decosterd LA, Buclin T, Majcherczyk PA, Sanglard D, Marchetti O. Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods. Antimicrob Agents Chemother. 2007 Jan;51(1):137-43 Article
Mulanovich V, Lewis RE, Raad II, Kontoyiannis DP. Random plasma concentrations of voriconazole decline over time. J Infect. 2007 Nov;55(5):e129-30 Article
Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007 Apr 15;109(8):1532-5 Article
Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial. Clin Infect Dis. 2007 Jan 1;44(1):2-12Article
Viscoli C, Herbrecht R, Akan H, Baila L, Doyen C, Gallamini A, Giagounidis A, Marchetti O, Martino R, Meerts L, Paesmans M, Shivaprakash M, Ullmann AJ, Maertens J, Caspofungin (C) as first-line therapy of invasive aspergillosis (IA) in haematological patients (pts): a study of the EORTC Infectious Diseases Group. Abstract 0.12. Trends in Medical Mycology, Turin, October 29-31st 2007 Abstract
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008 Feb 1;46(3):327-60 Article
Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008 Jan 15;46(2):201-11 Article
References:
Case histories: